Elyse Stock Biography and Net Worth

Insider of Biohaven

Dr. Stock has 30 years of clinical and drug development experience. After practicing psychiatry for 11 years she joined the pharmaceutical industry. Within the industry, Dr. Stock has spent the last 19 years at Bristol-Myers Squibb developingnumerous experimental agents across multiple therapeutic areas including neuroscience, oncology, immunology and cardiovascular. She has led numerous large and complex programs across all aspects of development including those leading to the marketing of products such as ABILIFY®, ORENCIA®, and EMPLICITI®. She is an experienced developer of both biologic and non-biologic compounds. Dr. Stock completed her residency at Payne Whitney Clinic, Cornell Medical Center and her fellowship in Child and Adolescent Psychiatry at Children’s Hospital National Medical Center in Washington D.C. She earned her medical degree at New York University School of Medicine.

What is Elyse Stock's net worth?: The estimated net worth of Elyse Stock is at least $1.00 million as of June 12th, 2020. Dr. Stock owns 22,560 shares of Biohaven stock worth more than $1,003,920 as of December 3rd. This net worth approximation does not reflect any other investments that Dr. Stock may own. Learn More about Elyse Stock's net worth.
How do I contact Elyse Stock?: The corporate mailing address for Dr. Stock and other Biohaven executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven can also be reached via phone at 203-404-0410 and via email at [email protected]. Learn More on Elyse Stock's contact information.
Has Elyse Stock been buying or selling shares of Biohaven?: Elyse Stock has not been actively trading shares of Biohaven over the course of the past ninety days. Most recently, Elyse Stock sold 21,919 shares of the business's stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $105.49, for a transaction totalling $2,312,235.31. Learn More on Elyse Stock's trading history.
Who are Biohaven's active insiders?: Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.
Are insiders buying or selling shares of Biohaven?: In the last twelve months, Biohaven insiders bought shares 8 times. They purchased a total of 307,186 shares worth more than $12,231,711.54. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 11,000 shares worth more than $459,690.00. The most recent insider tranaction occured on October, 2nd when Director John W Childs bought 21,052 shares worth more than $999,970.00. Insiders at Biohaven own 16.0% of the company. Learn More about insider trades at Biohaven.
Information on this page was last updated on 10/2/2024.

Elyse Stock Insider Trading History at Biohaven

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/15/2021	Sell	21,919	$105.49	$2,312,235.31
6/12/2020	Sell	36,966	$66.00	$2,439,756.00	22,560
10/18/2019	Sell	17,700	$45.07	$797,739.00	17,700
10/15/2019	Sell	800	$45.01	$36,008.00	800

Elyse Stock Buying and Selling Activity at Biohaven

Biohaven Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $44.50

$43.73

$45.39

50 Day Range

MA: $49.74

$44.37

$53.73

2 Week Range

Now: $44.50

$26.80

$62.21

Volume

197,820 shs

Average Volume

1,122,407 shs

Market Capitalization

$4.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.